US Patent 10196429 None
Patent 10196429 was granted and assigned to Pfizer Limited on February, 2019 by the United States Patent and Trademark Office.
All edits
Edits on 8 Dec, 2023
Golden AI
Edits made to:
Article (+419 characters)
Article
Patent abstract
In one aspect, the invention relates to a non-lipidated and non-pyruvylated Neisseria meningitidis serogroup B subfamily A A12 polypeptide. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from Neisseria meningitidis serogroup B, and at least one conjugated capsular saccharide from a meningococcal serogroup.
Edits on 2 Oct, 2023
Golden AI
Edits made to:
Infobox (+5 properties)
Infobox
Patent Inventor Names
Annaliesa Sybil Anderson0
Justin Keith Moran0
Kathrin Ute Jansen0
Mark E. Ruppen0
Susan Kay Hoiseth0
Edits on 21 Jun, 2023
Golden AI
Edits on 30 Mar, 2023
Golden AI
Infobox
Patent Citations Received
Edits on 28 Oct, 2022
Golden AI
Edits on 25 Sep, 2022
Golden AI
Infobox
Patent Citations Received
Edits on 9 Feb, 2022
Golden AI
Golden AI
Edits on 7 Feb, 2022
Golden AI
Golden AI
Edits on 24 Jan, 2022
Golden AI
Edits made to:
Infobox (+9 properties)
US Patent 10196429 None
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
10196429
Date of patent
February 5, 2019
Patent application number
15630147
Date Filed
June 22, 2017
Patent primary examiner
Find more entities like US Patent 10196429 None
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
